Omeprazole and Antihistamine Market

Omeprazole and Antihistamine Market Analysis

The Omeprazole And Antihistamine Market is expected to register a CAGR of 5.7% during the forecast period.

Factors such as the growing prevalence of gastroesophageal reflux disease (GERD), increasing demand for over-the-counter (OTC) medications, and rising awareness about the benefits of proton pump inhibitors (PPIs) are expected to fuel market growth. For instance, in August 2022, a research study published in Springer Nature stated that GERD was one of the most widespread gastrointestinal conditions, affecting 20% of adults in Western societies.

Males tend to have GERD at a slightly higher rate than females. In contrast to males, who are more expected to have erosive esophagitis, females who have GERD symptoms are more likely to have non-erosive reflux disease. Thus, the increasing prevalence of GERD is expected to increase the demand for PPI-based drugs. PPIs are the preferred medications because they prevent the stomach parietal cells from producing acid, which lessens the acid's ability to irritate the esophagus.

Similarly, increasing demand for over-the-counter (OTC) medications is expected to fuel the growth of the market studied during the forecast period. For instance, according to an article published by Bloomberg LP in July 2022, Americans spent an average cost of USD 1,300 per person on prescription drugs per year.

Therefore, the high burden of GERD among the population and the rising demand for over-the-counter drugs in the market are anticipated to propel the growth of the market during the forecast period. However, side effects associated with PPIs and increasing competition from generic drugs are expected to hinder market growth.

Omeprazole and Antihistamine Market Trends

Capsule Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Factors such as the increasing prevalence of stomach ulcers, coupled with product launches, are expected to fuel the segment’s growth during the forecast period. For instance, in April 2023, an article published in the National Library of Medicine (NLM) stated that gastric ulcers were a part of peptic ulcer disease, carrying a lifetime prevalence in 5% to 10% of patients. This was likely an underestimation of the disease as some patients were expected to remain asymptomatic. Studies have shown that the prevalence of gastric ulcers increases with age and the chronicity of non-steroidal anti-inflammatory drugs (NSAID).

Research shows that smoking leads to a relative risk of two times that of non-smokers for developing gastric ulcers. There is no difference between men and women in the prevalence of gastric ulcers. The approximate prevalence of helicobacter pylori infection among individuals aged 60 years in the US population is around 50%. Furthermore, estimates suggest that about 25% of chronic NSAID users will develop gastric ulcers.

Furthermore, initiatives such as increasing product approval and launches are expected to fuel the segment’s growth during the forecast period. In March 2023, Par Pharmaceutical Inc. introduced a generic version of Allergen Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) capsules in the United States. This launch came after receiving final approval from the Food and Drug Administration for its abbreviated new drug application. As a result, the growing prevalence of stomach ulcers, combined with the introduction of new products in the market, is anticipated to drive segmental growth during the forecast period.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

The North American market for omeprazole and antihistamines is anticipated to witness significant growth over the forecast period, owing to factors such as the increasing prevalence of diseases such as gastric ulcers and GERD, coupled with product launches by key players across the region.

The high burden of gastrointestinal disorders among the population raises the demand for effective therapeutics, which, in turn, is anticipated to propel the market’s growth during the forecast period. For instance, in November 2022, an article published by the Canadian Paediatric Society (CPS) stated that regurgitation or vomiting following most feeds was reported in 20% of healthy infants at one month of age. This can increase to 41% between three and four months of age, then subsequently decrease, becoming rare after one year of age. Thus, such a high number of infants suffering from GERD is expected to increase the demand for omeprazole-based drugs. Thus, the increasing prevalence of such diseases is expected to increase the demand for omeprazole and antihistamine-based drugs in the region.

Furthermore, product approvals are another factor driving market growth. For instance, in September 2022, the Food and Drug Administration (FDA) granted approval for Azurity Pharmaceuticals' Konvomep (omeprazole and sodium bicarbonate for oral suspension) to treat active benign gastric ulcers.

Thus, the increasing prevalence of diseases such as gastric ulcers and GERD, coupled with product launches, is expected to fuel market growth in the region.

Omeprazole and Antihistamine Industry Overview

The omeprazole and antihistamine market is consolidated in nature due to the presence of companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well-known, such as Bayer AG, Novartis, Pfizer, Procter & Gamble, and Teva Pharmaceutical.

Omeprazole and Antihistamine Market Leaders

Omeprazole and Antihistamine Market News

• February 2024: Alkaloid developed the ready-to-use liquid omeprazole, which is primarily designed to treat reflux esophagitis and GERD in young children unable to swallow tablets, as well as in adult patients who have difficulty swallowing.
• March 2023: Tiefenbacher Pharmaceuticals launched bilastine, an innovative anti-allergy medicine for patients suffering from allergic symptoms, such as hay fever and urticaria, as an over-the-counter (OTC) drug in Germany.